Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GeneFrontier is a Japanese biotechnology company that specializes in advanced protein synthesis and antibody discovery technologies. The company's flagship platform, PUREfrex, is a reconstituted cell-free protein synthesis system that enables the rapid production of high-purity proteins without the need for living cells. GeneFrontier also offers the ADLib system, a unique technology for generating monoclonal antibodies through the diversification of immunoglobulin genes in chicken DT40 cells. As a subsidiary of Kaneka Corporation, the company provides essential tools and contract research services to pharmaceutical companies and academic researchers worldwide. Their expertise spans from protein engineering to the development of specialized reagents for drug discovery and diagnostics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GeneFrontier.